Multiple myeloma is a cancer of plasma cells in the bone marrow that affects thousands of people annually in the United States. 1 Advances in treatment have steadily improved survival rates, with the current 5-year relative survival around 62%, reflecting better disease management and new therapies. 2 Despite these gains, multiple myeloma remains largely incurable but is increasingly treated as a chronic condition with prolonged survival. 3
Multiple Myeloma Disease Progression
Multiple myeloma progresses through stages defined by tumor burden, biological markers, and genetic abnormalities. The Revised International Staging System (RISS) is the most widely used classification, incorporating serum albumin, beta-2 microglobulin, lactate dehydrogenase (LDH), and cytogenetic abnormalities to stratify patients into three prognostic stages. 4
Interleukin-6 (IL-6) is a cytokine that promotes myeloma cell growth and survival. It also suppresses albumin production, contributing to hypoalbuminemia, a key prognostic factor. 5 Elevated beta-2 microglobulin reflects tumor burden, while high LDH levels indicate aggressive disease and rapid progression. 4 Molecular testing for cytogenetic abnormalities further refines prognosis and guides treatment decisions. 4
Stage 1
Stage 1 multiple myeloma is characterized by lower tumor burden and favorable laboratory parameters. Patients typically have higher serum albumin, lower beta-2 microglobulin, and normal LDH levels. Cytogenetic abnormalities are absent or standard risk. This stage reflects less aggressive disease and is associated with better survival outcomes. 4
Stage 2
Stage 2 represents an intermediate disease burden with moderate elevations in beta-2 microglobulin or LDH and possible presence of some cytogenetic abnormalities. Serum albumin may be decreased due to IL-6 mediated inflammation. Patients in this stage have a more variable prognosis depending on additional risk factors. 45
Stage 3
Stage 3 indicates advanced disease with high tumor burden, elevated beta-2 microglobulin and LDH, and often high-risk cytogenetic abnormalities such as del(17p), t(4;14), or gain(1q). These patients have aggressive disease biology and poorer prognosis, requiring more intensive treatment approaches. 4
Multiple Myeloma Survival Rates
Survival rates for multiple myeloma have improved significantly over recent decades due to novel therapies and better supportive care. The overall 5-year relative survival rate is approximately 61–62%, based on recent population data from 2015 to 2021. 672
The American Cancer Society reports a 5-year relative survival of about 81% for localized disease (solitary plasmacytoma) and 62% for distant disease (multiple myeloma). 2 However, only a small proportion (around 3.4%) of patients are diagnosed at the localized stage. 8
Survival statistics are averages based on large groups and do not predict individual outcomes due to variability in patient and disease factors. 9 Improvements in survival are expected to continue with ongoing therapeutic innovations such as CAR T-cell therapy, bispecific antibodies, and immunomodulatory drugs. 38
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Localized (solitary plasmacytoma) | 81% 2 |
| Distant (multiple myeloma) | 62% 2 |
| All stages combined | 62% 2 |
Prognosis Factors for Multiple Myeloma
Prognosis in multiple myeloma depends on a combination of patient characteristics, disease biology, and treatment response. Key factors include:
-
Age and Comorbidities: Younger patients generally tolerate intensive therapies better and achieve longer survival. Older patients with comorbidities may have limited treatment options and poorer outcomes. 410
-
Disease Stage: Early-stage disease is easier to control and linked to longer survival, while advanced stages have worse prognosis. 49
-
Cytogenetic Abnormalities: High-risk genetic changes such as del(17p), t(4;14), t(14;16), and gain(1q) are associated with aggressive disease and poorer survival. The presence of multiple high-risk factors (double-hit or triple-hit myeloma) further worsens prognosis. 411
-
Laboratory Markers: Elevated beta-2 microglobulin and LDH levels indicate higher tumor burden and aggressive disease. Low serum albumin reflects inflammation and poorer prognosis. 45
-
Treatment Response: Achieving deep remission, including minimal residual disease (MRD) negativity, predicts improved long-term survival. 12
-
Organ Damage: Renal impairment and bone disease worsen prognosis and complicate management. 513
-
Performance Status: Good functional status correlates with better treatment tolerance and outcomes. 4
Living With Multiple Myeloma
Living with multiple myeloma requires comprehensive care addressing physical symptoms, emotional health, and social support. Management focuses on controlling disease progression, minimizing complications, and maintaining quality of life. 145
Key aspects of living with multiple myeloma include:
-
Adherence to Treatment: Following prescribed therapies improves symptom control and survival. 5
-
Nutrition: Good nutrition supports immune function and overall health during treatment. 5
-
Exercise: Physical activity helps improve function and reduce fatigue. 5
-
Psychosocial Support: Counseling and support groups assist with emotional challenges and coping. 5
-
Monitoring and Follow-up: Regular medical visits and laboratory tests are essential to detect relapse early and adjust treatment. 15
-
Managing Side Effects: Addressing treatment-related side effects such as infections, bone pain, and fatigue is critical. 5
-
Emerging Therapies: Patients may benefit from new treatments like CAR T-cell therapy and bispecific antibodies, which offer hope for longer remission and improved outcomes. 168
“Historically, multiple myeloma is a disease that relapses again and again, even after the best available treatments. Most patients require continuous therapy, sometimes for years. But the landscape is changing dramatically and CAR T-cell therapy is leading to a level of durable remission, off treatment, that is unprecedented in myeloma care.”
— Ehsan Malek, MD, PhD, Roswell Park Comprehensive Cancer Center16
Multiple Myeloma Prognosis Summary
Multiple myeloma prognosis is influenced by a complex interplay of disease stage, genetic risk factors, patient health, and treatment response. The Revised International Staging System (RISS) remains the cornerstone for risk stratification, combining clinical and molecular markers to guide prognosis and therapy. 414
Survival has improved markedly due to novel agents such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and advanced cellular therapies. Median survival now approaches 6 years or more, with some patients achieving long-term remission, especially those eligible for autologous stem cell transplantation (ASCT). 181920
Despite these advances, multiple myeloma remains largely incurable, but is increasingly managed as a chronic disease with ongoing treatment and monitoring. Future therapies aim to deepen remission, reduce relapse, and potentially achieve true cure through immunotherapy and targeted approaches. 3178
Key takeaways:
- Multiple myeloma is staged by RISS into three prognostic groups based on tumor burden and biology. 4
- Survival rates have improved to about 62% at 5 years, with better outcomes in early-stage disease. 27
- High-risk cytogenetics and organ damage worsen prognosis, while deep treatment responses improve survival. 412
- New therapies, including CAR T-cell therapy and bispecific antibodies, are transforming treatment and survival. 168
- Comprehensive care addressing physical, emotional, and social needs is essential for quality of life. 5
